CORE LABORATORIES N V (CLB) [Rocket]

Overview

CORE LABORATORIES N V (CLB)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
06/12/2023	SC 13G/A	ALGER ASSOCIATES INC reports a 0% stake in Core Laboratories N.V.
05/02/2023	25-NSE	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/27/2023	10-Q	Quarterly Report for the period ended March 31, 2023
04/26/2023	8-K	Quarterly results
04/03/2023	4	van Dijken Eeuwijk Monique (Director) has filed a Form 4 on CORE LABORATORIES N V
04/03/2023	4	Temeng Kwaku (Director) has filed a Form 4 on CORE LABORATORIES N V
04/03/2023	4	Straughen Michael (Director) has filed a Form 4 on CORE LABORATORIES N V

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	470.3	487.3	668.2	700.8	647.8	550.8	797.5	1,085.2
Revenue growth	-3.5%	-27.1%	-4.7%	8.2%	17.6%	-30.9%	-26.5%	1.1%
Cost of goods sold	0.0	0.0	0.0	559.9	512.7	437.5	532.7	665.3
Gross profit	470.3	487.3	668.2	141.0	135.1	113.3	264.9	420.0
Gross margin	100.0%	100.0%	100.0%	20.1%	20.9%	20.6%	33.2%	38.7%
Selling, general and administrative	0.0	114.0	0.0	22.4	25.2	25.9	54.1	26.7
EBITA	33.6	22.1	81.8	119.7	110.9	88.3	184.9	347.9
EBITA margin	7.1%	4.5%	12.2%	17.1%	17.1%	16.0%	23.2%	32.1%
Amortization of intangibles				1.1	0.9	0.8	0.9	1.4
EBIT	33.6	22.1	81.8	118.6	110.0	87.5	184.0	346.5
EBIT margin	7.1%	4.5%	12.2%	16.9%	17.0%	15.9%	23.1%	31.9%
Pre-tax income	36.1	-91.2	82.0	105.3	99.2	75.9	148.7	335.9
Income taxes	15.9	5.9	-12.3	25.4	18.2	10.9	33.8	77.3
Tax rate	44.0%			24.2%	18.4%	14.3%	22.7%	23.0%
Net income	19.7	-97.6	102.0	159.4	83.1	63.9	114.8	257.5
Net margin	4.2%	-20.0%	15.3%	22.7%	12.8%	11.6%	14.4%	23.7%

Diluted EPS	$0.42	($2.20)	$2.28	$3.58	$1.88	$1.46	$2.68	$5.77
Shares outstanding (diluted)	46.7	44.5	44.6	44.5	44.3	43.7	42.9	44.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.